Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy

Next Previous
Trial Profile

A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dostarlimab (Primary) ; Niraparib (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel; Topotecan
  • Indications Carcinoma; Endometrial cancer; Ovarian cancer; Sarcoma
  • Focus Therapeutic Use
  • Acronyms ROCSAN

Most Recent Events

  • 08 Jul 2025 Planned number of patients changed from 196 to 138.
  • 08 Jul 2025 Status changed from active, no longer recruiting to recruiting.
  • 08 Jul 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top